Abstract
Time for Integrating Clinical, Lifestyle and Molecular Data to Predict Drug Responses
Highlights
The study performed by Pottegård and colleagues, published in this issue of EBioMedicine (Pottegård et al, 2016), falls within the clinically relevant scientific field which focuses on the variability in human drug response (Bruno et al, 2014; Fitzgerald, 2005)
The analysis of cancer risk association with the use of single drugs (510 signals) suggested that 33% and 67% of them were linked to a reduction and an increase of cancer risk, respectively
Antiplatelet agents may act as anti-cancer drugs by inhibiting the release of several platelet mediators which may contribute to the development of chronic inflammation associated with hepatocellular carcinoma (HCC)
Summary
The occurrence of these determinants in drug response has provided the basis for the development of precision medicine, i.e., prevention and treatment strategies that take individual variability into account (FitzGerald, 2015; Collins and Varmus, 2015). They performed a large-scale systematic screening for identifying associations between prescribed drugs and cancer risk using the high quality Danish nationwide health and demographic registries.
Sign-in/Register to view highlights & summary 
Published Version (
Free)
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call